.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Citi
Covington
Fish and Richardson
Deloitte
US Army
AstraZeneca
Johnson and Johnson
Mallinckrodt

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,420,674

« Back to Dashboard

Which drugs does patent 8,420,674 protect, and when does it expire?


Patent 8,420,674 protects ESBRIET and is included in two NDAs.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 8,420,674

Title:Method of providing pirfenidone therapy to a patient
Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
Inventor(s): Bradford; Williamson Z. (Ross, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:12/831,944
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genentech IncESBRIETpirfenidoneCAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► SubscribeYDOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,420,674

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,696,236Method of providing pirfenidone therapy to a patient► Subscribe
7,767,700Method of providing pirfenidone therapy to a patient► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,420,674

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark2124945► Subscribe
Slovenia2124945► Subscribe
Portugal2124945► Subscribe
Mexico2009006526► Subscribe
Japan2010513320► Subscribe
Hong Kong1153647► Subscribe
Hong Kong1133584► Subscribe
Spain2581844► Subscribe
Spain2395396► Subscribe
European Patent Office3053580► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Fuji
Federal Trade Commission
Fish and Richardson
Accenture
Colorcon
US Army
Moodys
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot